Miscellaneous ocular agents:
Indications for: SYFOVRE
Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
See full labeling. Each vial is for use in a single eye. Give by intravitreal inj to each affected eye. 15mg (0.1mL of 150mg/mL solution) once every 25 to 60 days.
Ocular or periocular infection. Active intraocular inflammation.
Must be administered by a qualified physician. Monitor for elevated IOP prior to initiation and following inj (may give ocular hypotensive meds if needed). Monitor for endophthalmitis, retinal detachments, neovascular AMD, and perfusion of the optic nerve head following inj. Risk for intraocular inflammation; may resume after resolution. Advise females of reproductive potential to use effective contraception during and for 40 days after the last dose. Pregnancy. Nursing mothers.
If anti-VEGF is required, give separately from Syfovre administration.
Ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage; intraocular inflammation.
Estimated geometric mean (%CV) of clearance (CL): 0.284 L/day (21.1%). Geometric mean half-life: 4.5 days (21.1%).
Generic Drug Availability: